Latest post

“An aspiring name to reflect our focus and ambition”

“The new name comes from combining the words Oxygen and Orion”, explains CEO Patrik De Haes, MD. “Raising oxygen levels in cells plays a key role in helping prevent and reverse ...

back of the eye diseases, science community

“We need therapies fighting different hallmarks simultaneously”

PDR and DME are two manifestations of diabetic retinopathy (DR), and in many respects they stem from the same cause, explains Prof. Alan Stitt, Dean of Innovation & Impact and ...

back of the eye diseases, science community

“Developing novel drugs through collaboration and strong science”

“We work as a complimentary team, putting Oxurion in a unique position as a very agile biotech company,” says Susan Schneider, who joined the company’s leadership team in 2017 ...